
Yao Laboratory
Wantong Yao, M.D., Ph.D.
Principal Investigator
- Departments, Labs and Institutes
- Labs
- Yao Laboratory
Areas of Research
- Pancreatic Cancer Research
- Sarcoma Research
- Genetics Functional Screen Research
- Cancer Biology Research
- Immunology Research
- Targeted Therapy Research
The Yao Laboratory is interested in identifying context-specific druggable vulnerabilities for oncogenic signaling and function, with a specific focus on studying cell membrane proteins (e.g. Surfaceome.)
Contact Us
Wantong Yao, M.D., Ph.D.
Principal Investigator
Assistant Professor, Department of Translational Molecular Pathology
The University of Texas MD Anderson Cancer Center
Email: WYao2@mdanderson.org
We're Hiring
The Yao Lab is looking for students and postdoctoral fellows who are interested in mechanism-based translational research on pancreatic cancer and soft tissue sarcoma. We welcome our next generation of scientists from life science, chemistry and engineering fields to join us!
Selected Publications
-
Cell
Hear Pancreatic Cancer Stem Cells ROR.
Yao W, Maitra A. Cell 177(3):516-518, 4/2019.
-
Nature
Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer.
Yao W, Rose JL, Wang W, Seth S, Jiang H, Taguchi A, Liu J, Yan L, Kapoor A, Hou P, Chen Z, Wang Q, Nezi L, Xu Z, Yao J, Hu B, Pettazzoni PF, Ho IL, Feng N, Ramamoorthy V, Jiang S, Deng P, Ma GJ, Den P, Tan Z, Zhang SX, Wang H, Wang YA, Deem AK, Fleming JB, Carugo A, Heffernan TP, Maitra A, Viale A, Ying H, Hanash S, DePinho RA, Draetta GF. Nature 568(7752):410-414, 4/2019. e-Pub 3/2019.
-
Cell
Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer.
Kapoor A, Yao W (co-first), Ying H, Hua S, Liewen A, Wang Q, Zhong Y, Wu CJ, Sadanandam A, Hu B, Chang Q, Chu GC, Al-Khalil R, Jiang S, Xia H, Fletcher-Sananikone E, Lim C, Horwitz GI, Viale A, Pettazzoni P, Sanchez N, Wang H, Protopopov A, Zhang J, Heffernan T, Johnson RL, Chin L, Wang YA, Draetta G, DePinho RA. Cell 158(1):185-197, 7/2014. e-Pub 6/2014.
-
Mol Cancer
Profilin-1 suppresses tumorigenicity in pancreatic cancer through regulation of the SIRT3-HIF1α axis.
Yao W, Ji S, Qin Y, Yang J, Xu J, Zhang B, Xu W, Liu J, Shi S, Liu L, Liu C, Long J, Ni Q, Li M, Yu X. Mol Cancer 13:187, 8/2014. e-Pub 8/2014.
-
Cancer Res
Targeting glucose metabolism sensitizes pancreatic cancer to MEK inhibition.
Yan L, Tu B, Yao J, Gong J, Carugo A, Bristow C, Wang Q, Zhu C, Dai B, Kang Y, Han L, Feng N, Jin Y, Fleming J, Heffernan T, Yao W (co-corresponding), Ying H. Cancers Res. 2021 Jun 11;canres.3792.2020. doi: 10.1158/0008-5472.CAN-20-3792
-
Cell Death & Disease
Suppression of tumor angiogenesis by targeting protein neddylation pathway
Yao W, Wu J, Yu G, Wang R, Wang K, Li L, Chen P, Jiang Y, Cheng H, Lee H, Hoffman R, Jeong L, Jia L. Cell Death & Disease, 2/2014.
-
EBioMedicine
Recent insights into the biology of pancreatic cancer.
Yao W, Maitra A, Ying H. EBioMedicine. 2020 Mar;53:102655
-
JCI Insight
YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma.
Tu B, Yao J, Ferri-Borgogno S, Zhao J, Chen S, Wang Q, Yan L, Zhou X, Zhu C, Bang S, Chang Q, Bristow CA, Kang Y, Zheng H, Wang H, Fleming JB, Kim M, Heffernan TP, Draetta GF, Pan D, Maitra A, Yao W (co-corresponding), Gupta S, Ying H. JCI Insight 4(21), 11/2019. e-Pub 11/2019.
Life in the Yao Lab



